Nebulised heparin as a treatment for COVID-19: scientific rationale and a call for randomised evidence

被引：0

作者：

Frank M. P. van Haren

Clive Page

John G. Laffey

Antonio Artigas

Marta Camprubi-Rimblas

Quentin Nunes

Roger Smith

Janis Shute

Mary Carroll

Julia Tree

Miles Carroll

Dave Singh

Tom Wilkinson

Barry Dixon

机构：

[1] Australian National University,Intensive Care Unit

[2] Medical School,Sackler Institute of Pulmonary Pharmacology

[3] the Canberra Hospital,Anaesthesia and Intensive Care Medicine, School of Medicine, and Regenerative Medicine Institute (REMEDI) at CÚRAM Centre for Research in Medical Devices, Biomedical Sciences Building

[4] King’s College London,Department of Anaesthesia, University Hospital Galway

[5] National University of Ireland Galway,Critical Center, Corporació Sanitaria Parc Tauli , CIBER Enfermedades Respiratorias

[6] Saolta Hospital Group,Institut d’Investigació I Innovació Parc Tauli (I3PT)

[7] Autonomous University of Barcelona,Institute of Systems, Molecular and Integrative Biology

[8] CIBER de Enfermedades Respiratorias,Department of Critical Care Medicine

[9] University of Liverpool,School of Pharmacy and Biomedical Science

[10] St Vincent’s Hospital,Department of Respiratory Medicine

[11] University of Portsmouth,National Infection Service

[12] University of Southampton,Medicines Evaluation Unit

[13] Public Health England,undefined

[14] University of Manchester,undefined

来源：

Critical Care | / 24卷

关键词：

COVID-19; ARDS; SARS; Nebulised heparin; Unfractionated heparin; SARS-CoV-2;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Nebulised unfractionated heparin (UFH) has a strong scientific and biological rationale and warrants urgent investigation of its therapeutic potential, for COVID-19-induced acute respiratory distress syndrome (ARDS). COVID-19 ARDS displays the typical features of diffuse alveolar damage with extensive pulmonary coagulation activation resulting in fibrin deposition in the microvasculature and formation of hyaline membranes in the air sacs. Patients infected with SARS-CoV-2 who manifest severe disease have high levels of inflammatory cytokines in plasma and bronchoalveolar lavage fluid and significant coagulopathy. There is a strong association between the extent of the coagulopathy and poor clinical outcomes.

引用

共 50 条

[1] Nebulised heparin as a treatment for COVID-19: scientific rationale and a call for randomised evidence
van Haren, Frank M. P.
Page, Clive
Laffey, John G.
Artigas, Antonio
Camprubi-Rimblas, Marta
Nunes, Quentin
Smith, Roger
Shute, Janis
Carroll, Mary
Tree, Julia
Carroll, Miles
Singh, Dave
Wilkinson, Tom
Dixon, Barry
CRITICAL CARE, 2020, 24 (01)
[2] Inhaled nebulised unfractionated heparin (UFH) for the treatment of hospitalised patients with COVID-19: A randomised controlled pilot study
DeNucci, Gilberto
Wilkinson, Tom
Sverdloff, Carlos
Babadopulos, Tainah
Woodcock, Ashley
Shute, Jan
Guazelli, Pedro Renato
Gerbase, Luis Frederico
Mourao, Paulo A. S.
Singh, Dave
van Haren, Frank M. P.
Page, Clive
PULMONARY PHARMACOLOGY & THERAPEUTICS, 2023, 80
[3] Inhaled nebulised unfractionated heparin for the treatment of hospitalised patients with COVID-19: A multicentre case series of 98 patients
van Haren, Frank M. P.
van Loon, Lex M.
Steins, Anne
Smoot, Thomas L.
Sas, Caitlin
Staas, Sabrina
Vilaseca, Alicia B.
Barbera, Ruben A.
Vidmar, Gustavo
Beccari, Hugo
Popilevsky, Frida
Daribayeva, Eleonora
Venkatesan, Bhuvaneshwari
Mozes, Susan
Postel, Rachel
Popilevski, Natalie
Webb, Andrew
Nunes, Quentin
Laffey, John G.
Artigas, Antonio
Smith, Roger
Dixon, Barry
Richardson, Alice
Yoon, Hwan-Jin
Page, Clive
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (06) : 2802 - 2813
[4] INHALEd nebulised unfractionated HEParin for the treatment of hospitalised patients with COVID-19 (INHALE-HEP): Protocol and statistical analysis plan for an investigator-initiated international metatrial of randomised studies
van Haren, Frank M. P.
Richardson, Alice
Yoon, Hwan-Jin
Artigas, Antonio
Laffey, John G.
Dixon, Barry
Smith, Roger
Vilaseca, Alicia B.
Barbera, Ruben A.
Ismail, Tarek I.
Mahrous, Rabab S.
Badr, Mohamed
De Nucci, Gilberto
Sverdloff, Carlos
van Loon, Lex M.
Camprubi-Rimblas, Marta
Cosgrave, David W.
Smoot, Thomas L.
Staas, Sabrina
Sann, Khine
Sas, Caitlin
Belani, Anusha
Hillman, Christopher
Shute, Janis
Carroll, Mary
Wilkinson, Tom
Carroll, Miles
Singh, Dave
Page, Clive
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 87 (08) : 3075 - 3091
[5] A randomised, open-label trial of nebulised unfractionated heparin in patients mechanically ventilated for COVID-19
Smith, Roger J.
Ghosh, Angajendra N.
Said, Simone
van Haren, Frank M. P.
Laffey, John G.
Doig, Gordon S.
Santamaria, John D.
Dixon, Barry
ANAESTHESIA AND INTENSIVE CARE, 2025,
[6] Antithrombotic therapy in patients with COVID-19? -Rationale and Evidence-
Godino, Cosmo
Scotti, Andrea
Maugeri, Norma
Mancini, Nicasio
Fominskiy, Evgeny
Margonato, Alberto
Landoni, Giovanni
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2021, 324 : 261 - 266
[7] Can nebulised HepArin Reduce morTality and time to Extubation in patients with COVID-19 Requiring invasive ventilation Meta-Trial (CHARTER-MT): Protocol and statistical analysis plan for an investigator-initiated international meta-trial of prospective randomised clinical studies
van Haren, Frank M. P.
Laffey, John G.
Artigas, Antonio
Page, Clive
Schultz, Marcus J.
Cosgrave, David
McNicholas, Bairbre
Smoot, Thomas L.
Nunes, Quentin
Richardson, Alice
Yoon, Hwan-Jin
van Loon, Lex M.
Ghosh, Angajendra
Said, Simone
Panwar, Rakshit
Smith, Roger
Santamaria, John D.
Dixon, Barry
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (07) : 3272 - 3287
[8] Rationale for the Role of Heparin and Related GAG Antithrombotics in COVID-19 Infection
Magnani, Harry N.
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2021, 27
[9] Rationale for azithromycin in COVID-19: an overview of existing evidence
Gyselinck, Iwein
Janssens, Wim
Verhamme, Peter
Vos, Robin
BMJ OPEN RESPIRATORY RESEARCH, 2021, 8 (01)
[10] Heparin therapy in COVID-19: Call for randomized controlled trials (RCTs)
Fang, Tingting
Pan, Xianyang
Huang, Ju
Chen, Jun
Song, Shuli
Zhan, Qilin
BIOSCIENCE TRENDS, 2022, 16 (04) : 307 - 311

← 1 2 3 4 5 →